Involvement of the Erk-MAP kinase pathway in TNFα regulation of trabecular matrix metalloproteinases and TIMPs

J. Preston Alexander, Ted Acott

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

PURPOSE. TNFα is a strong modulator expression of trabecular meshwork (TM) matrix metalloproteinase (MMP) and tissue inhibitor (TIMP). Laser trabeculoplasty appears to rely on this process to restore normal aqueous humor outflow facility. Thus, studies were conducted to determine whether the extracellular signal-regulated kinase (Erk)-mitogen-activated protein (MAP) kinase signal-transduction pathway is involved. METHODS. Porcine TM cells were treated with TNFα, and changes in MMPs and TIMPs were evaluated by zymography and Western immunoblot assay. Phosphospecific antibodies to proteins from the Erk pathway were used to evaluate responses to treatment with TNFα. Inhibitors of Mek, the kinase that activates Erk, and of protein kinase C (PKC) isoforms were used to define pathway involvement. RESULTS. Treatment with TNFα increased MMP-1, -3, and -9 and TIMP-1, whereas expression of MMP-2 was not affected and expression of TIMP-2 was decreased. Erk and Mek were rapidly phosphorylated after treatment with TNFα, and c-Raf-1 showed a significant bandshift. A specific inhibitor of Mek blocked the TNFα induction of the MMPs and TIMPs and the phosphorylation of Erk. An inhibitor of the PKC-μ isoform, which also blocks the effects of MMP-TIMP of TNFα, did not affect phosphorylation of Erk. CONCLUSIONS. The components of this MAP kinase pathway in the TM are dramatically affected by TNFα and inhibition of Erk's phosphorylation blocks the changes in MMP and TIMP expression. PKC μ, which is also required in this transduction process, does not appear to be upstream from Erk in the signaling cascade. Manipulation of this and related TM signal-transduction pathways may provide targets for developing improved glaucoma treatments.

Original languageEnglish (US)
Pages (from-to)164-169
Number of pages6
JournalInvestigative Ophthalmology and Visual Science
Volume44
Issue number1
DOIs
StatePublished - Jan 1 2003

Fingerprint

Extracellular Signal-Regulated MAP Kinases
Mitogen-Activated Protein Kinases
Matrix Metalloproteinases
Trabecular Meshwork
Protein Kinase C
Phosphorylation
Signal Transduction
Protein Isoforms
Phospho-Specific Antibodies
Tissue Inhibitor of Metalloproteinase-2
Matrix Metalloproteinase 3
Matrix Metalloproteinase 1
Trabeculectomy
Tissue Inhibitor of Metalloproteinase-1
Matrix Metalloproteinase Inhibitors
Aqueous Humor
Matrix Metalloproteinase 2
Glaucoma
Lasers
Phosphotransferases

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Involvement of the Erk-MAP kinase pathway in TNFα regulation of trabecular matrix metalloproteinases and TIMPs. / Alexander, J. Preston; Acott, Ted.

In: Investigative Ophthalmology and Visual Science, Vol. 44, No. 1, 01.01.2003, p. 164-169.

Research output: Contribution to journalArticle

@article{2e005aff320d4de89a30a0001b9e0052,
title = "Involvement of the Erk-MAP kinase pathway in TNFα regulation of trabecular matrix metalloproteinases and TIMPs",
abstract = "PURPOSE. TNFα is a strong modulator expression of trabecular meshwork (TM) matrix metalloproteinase (MMP) and tissue inhibitor (TIMP). Laser trabeculoplasty appears to rely on this process to restore normal aqueous humor outflow facility. Thus, studies were conducted to determine whether the extracellular signal-regulated kinase (Erk)-mitogen-activated protein (MAP) kinase signal-transduction pathway is involved. METHODS. Porcine TM cells were treated with TNFα, and changes in MMPs and TIMPs were evaluated by zymography and Western immunoblot assay. Phosphospecific antibodies to proteins from the Erk pathway were used to evaluate responses to treatment with TNFα. Inhibitors of Mek, the kinase that activates Erk, and of protein kinase C (PKC) isoforms were used to define pathway involvement. RESULTS. Treatment with TNFα increased MMP-1, -3, and -9 and TIMP-1, whereas expression of MMP-2 was not affected and expression of TIMP-2 was decreased. Erk and Mek were rapidly phosphorylated after treatment with TNFα, and c-Raf-1 showed a significant bandshift. A specific inhibitor of Mek blocked the TNFα induction of the MMPs and TIMPs and the phosphorylation of Erk. An inhibitor of the PKC-μ isoform, which also blocks the effects of MMP-TIMP of TNFα, did not affect phosphorylation of Erk. CONCLUSIONS. The components of this MAP kinase pathway in the TM are dramatically affected by TNFα and inhibition of Erk's phosphorylation blocks the changes in MMP and TIMP expression. PKC μ, which is also required in this transduction process, does not appear to be upstream from Erk in the signaling cascade. Manipulation of this and related TM signal-transduction pathways may provide targets for developing improved glaucoma treatments.",
author = "Alexander, {J. Preston} and Ted Acott",
year = "2003",
month = "1",
day = "1",
doi = "10.1167/iovs.01-1201",
language = "English (US)",
volume = "44",
pages = "164--169",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "1",

}

TY - JOUR

T1 - Involvement of the Erk-MAP kinase pathway in TNFα regulation of trabecular matrix metalloproteinases and TIMPs

AU - Alexander, J. Preston

AU - Acott, Ted

PY - 2003/1/1

Y1 - 2003/1/1

N2 - PURPOSE. TNFα is a strong modulator expression of trabecular meshwork (TM) matrix metalloproteinase (MMP) and tissue inhibitor (TIMP). Laser trabeculoplasty appears to rely on this process to restore normal aqueous humor outflow facility. Thus, studies were conducted to determine whether the extracellular signal-regulated kinase (Erk)-mitogen-activated protein (MAP) kinase signal-transduction pathway is involved. METHODS. Porcine TM cells were treated with TNFα, and changes in MMPs and TIMPs were evaluated by zymography and Western immunoblot assay. Phosphospecific antibodies to proteins from the Erk pathway were used to evaluate responses to treatment with TNFα. Inhibitors of Mek, the kinase that activates Erk, and of protein kinase C (PKC) isoforms were used to define pathway involvement. RESULTS. Treatment with TNFα increased MMP-1, -3, and -9 and TIMP-1, whereas expression of MMP-2 was not affected and expression of TIMP-2 was decreased. Erk and Mek were rapidly phosphorylated after treatment with TNFα, and c-Raf-1 showed a significant bandshift. A specific inhibitor of Mek blocked the TNFα induction of the MMPs and TIMPs and the phosphorylation of Erk. An inhibitor of the PKC-μ isoform, which also blocks the effects of MMP-TIMP of TNFα, did not affect phosphorylation of Erk. CONCLUSIONS. The components of this MAP kinase pathway in the TM are dramatically affected by TNFα and inhibition of Erk's phosphorylation blocks the changes in MMP and TIMP expression. PKC μ, which is also required in this transduction process, does not appear to be upstream from Erk in the signaling cascade. Manipulation of this and related TM signal-transduction pathways may provide targets for developing improved glaucoma treatments.

AB - PURPOSE. TNFα is a strong modulator expression of trabecular meshwork (TM) matrix metalloproteinase (MMP) and tissue inhibitor (TIMP). Laser trabeculoplasty appears to rely on this process to restore normal aqueous humor outflow facility. Thus, studies were conducted to determine whether the extracellular signal-regulated kinase (Erk)-mitogen-activated protein (MAP) kinase signal-transduction pathway is involved. METHODS. Porcine TM cells were treated with TNFα, and changes in MMPs and TIMPs were evaluated by zymography and Western immunoblot assay. Phosphospecific antibodies to proteins from the Erk pathway were used to evaluate responses to treatment with TNFα. Inhibitors of Mek, the kinase that activates Erk, and of protein kinase C (PKC) isoforms were used to define pathway involvement. RESULTS. Treatment with TNFα increased MMP-1, -3, and -9 and TIMP-1, whereas expression of MMP-2 was not affected and expression of TIMP-2 was decreased. Erk and Mek were rapidly phosphorylated after treatment with TNFα, and c-Raf-1 showed a significant bandshift. A specific inhibitor of Mek blocked the TNFα induction of the MMPs and TIMPs and the phosphorylation of Erk. An inhibitor of the PKC-μ isoform, which also blocks the effects of MMP-TIMP of TNFα, did not affect phosphorylation of Erk. CONCLUSIONS. The components of this MAP kinase pathway in the TM are dramatically affected by TNFα and inhibition of Erk's phosphorylation blocks the changes in MMP and TIMP expression. PKC μ, which is also required in this transduction process, does not appear to be upstream from Erk in the signaling cascade. Manipulation of this and related TM signal-transduction pathways may provide targets for developing improved glaucoma treatments.

UR - http://www.scopus.com/inward/record.url?scp=0037247620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037247620&partnerID=8YFLogxK

U2 - 10.1167/iovs.01-1201

DO - 10.1167/iovs.01-1201

M3 - Article

C2 - 12506070

AN - SCOPUS:0037247620

VL - 44

SP - 164

EP - 169

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 1

ER -